Insmed to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, February 23, 2023

Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM) will release its fourth quarter and full year 2022 financial results on February 23, 2023. A conference call for investors is scheduled for 8:30 a.m. ET on the same day to discuss these results and provide a business update. Interested parties can join the call by dialing (844) 200-6205 (U.S.) or (929) 526-1599 (international), or by accessing the live webcast on the company's website. A replay will be available shortly after the event until March 25, 2023. Insmed is focused on serious and rare diseases, with its first therapy already approved in the U.S., Europe, and Japan.

BRIDGEWATER, N.J., Feb. 9, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth quarter and full year 2022 financial results on Thursday, February 23, 2023.

Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, February 23, 2023, to discuss the financial results and provide a business update.

Shareholders and other interested parties may participate in the conference call by dialing (844) 200-6205 (U.S.) or (929) 526-1599 (international) and referencing access code 397951. The call will also be webcast live on the company's website at www.insmed.com.

A replay of the conference call will be accessible approximately 30 minutes after its completion through March 25, 2023, by dialing (866) 813-9403 (U.S.) or (+44) 204-525-0658 (international) and referencing access code 828224. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.

Contact:

Investors:

Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com

Media:

Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-host-fourth-quarter-and-full-year-2022-financial-results-conference-call-on-thursday-february-23-2023-301738014.html

SOURCE Insmed Incorporated

FAQ

When will Insmed release its fourth quarter and full year 2022 financial results?

Insmed will release its financial results on February 23, 2023.

What time is the Insmed conference call for financial results?

The conference call is scheduled for 8:30 a.m. ET on February 23, 2023.

How can I participate in the Insmed conference call?

Participants can join by calling (844) 200-6205 (U.S.) or (929) 526-1599 (international), or by accessing the live webcast on Insmed's website.

Will there be a replay of the Insmed conference call?

Yes, a replay will be available until March 25, 2023.